Latest News
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
In the News
LATEST FINANCIAL RESULTS
Q2 2024
Quarter Ended Jun 30, 2024
Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.
LATEST ANNUAL FILING
Company Overview
At Telomir Pharmaceuticals, we are committed to developing breakthrough science to address the root causes of difficult to treat diseases. By partnering with the brightest minds in science and healthcare, we have the potential to discover and develop ground-breaking treatments to bring about better health for patients and change the future of medicine.
Symbol
NASDAQ: TELOPrice
$Volume
Change
Email Alerts
& get notified, as they happen
IR Contacts
Headquarters
Telomir Pharmaceuticals, Inc.
900 West Platt St.
Suite 200
Tampa, FL 33606-2173
United States
T: 813-864-2558
[email protected]
Investor Relations
Telomir Pharmaceuticals, Inc.
900 West Platt St.
Suite 200
Tampa, FL 33606-2173
United States
T: 813-864-2558
[email protected]
Transfer Agent
Equiniti
6201 15th Avenue.
Brooklyn, NY 11219
T: US 800-401-1957
T: Canada/US Virgin Islands 800-468-9716
T: Other Internationl Access Codes
[email protected]